AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30343563
Drug: i-gel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i-gel®
Trial: 26871523
Drug: DEX implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX implant 0.7-mg
Trial: 26871523
Drug: DEX implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX implant 0.35-mg
Trial: 21484965
Drug: Infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab 5 or 10 mg/kg every 8 weeks
Trial: 20133962
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy (CBT) program, 10-month duration, three 2-hour group sessions per week
Trial: 18042509
Drug: Selegiline Transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline Transdermal System (STS) 3 mg/24 h
Trial: 18042509
Drug: Selegiline Transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline Transdermal System (STS) 6 mg/24 h
Trial: 12498526
Drug: Various pharmacologic
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various pharmacologic therapies (acetaminophen, traditional NSAIDs, COX-2 inhibitors, intra-articular steroids, viscosupplements, glucosamine, chondroitin sulfate, capsaicin)
Trial: 113626
Drug: Primary radiation
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radiation treatment
Trial: 30789432
Drug: Optimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal treatment selection rule based on predicted mean difference in outcomes comparing those with versus without treatment, conditional on covariates.
Trial: 30789432
Drug: Treatment selection
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment selection when resources are constrained.
Trial: 30789432
Drug: Treatment selection
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment selection when resources are not constrained.
Trial: 30789432
Drug: Treatment selection
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment selection in the presence of side effects and costs.
Trial: 30789432
Drug: Treatment selection
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment selection to maximize effect heterogeneity.
Trial: 28388820
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy and Methotrexate-etanercept
Trial: 19879683
Drug: E2/DRSP (17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/DRSP (17beta‐estradiol 1mg plus drospirenone 2 mg daily)
Trial: 19879683
Drug: E2/NETA (17beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2/NETA (17beta‐estradiol 1mg plus norethisterone acetate 0.5 mg daily)
Trial: 17144496
Drug: Rhino Rapid
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhino Rapid Nasal Dressing with Gel Knit
Trial: 14716694
Drug: donepezil+sertraline (50-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil+sertraline (50-200 mg)
Trial: 14716694
Drug: donepezil+sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil+sertraline
Trial: 9759799
Drug: Theophylline (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (target STC of 10 to 15 mg/L)
Trial: 30148973
Drug: Concurrent training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent training (combination of endurance and resistance training)
Trial: 29124831
Drug: Topical triamcinolone
RxNorm normalized name: triamcinolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical triamcinolone acetonide 0.1% oral paste
Trial: 29124831
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical triamcinolone acetonide 0.1% and oral methotrexate
Trial: 25044085
Drug: Topical testosterone
RxNorm normalized name: testosterone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical testosterone gel (1% T gel)
Trial: 20864808
Drug: Active vaccine
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vaccine (DNA prime, recombinant fowlpox virus boost)
Trial: 15080407
Drug: Deferiprone 50
RxNorm normalized name: deferiprone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferiprone 50 mg/kg
Trial: 15080407
Drug: Deferiprone 75
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 75 mg/kg
Trial: 11085324
Drug: MDMA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (50 to 150 mg)
Trial: 8173687
Drug: Felodipine-Metoprolol 10/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine-Metoprolol 10/100 mg
Trial: 971343
Drug: Cholestyramine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (16 g/day)
Trial: 3781686
Drug: Probucol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (1 g/day)
Trial: 3781686
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Probucol + Cholestyramine)
Trial: 3235476
Drug: Flosequinan (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan (single dose)
Trial: 3235476
Drug: Flosequinan (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flosequinan (chronic treatment)
Trial: 15545155
Drug: Co‐amilozide (diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co‐amilozide (diuretic combination)
Trial: 10740725
Drug: Y virilin
RxNorm normalized name: Neuropeptide Y
DrugBank: Neuropeptide Y (DB11788)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Y virilin (Treatment Group A)
Trial: 10740725
Drug: Placebo (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Treatment Group B)
Trial: 29559834
Drug: Oral Ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Ibuprofen (OI) for 6 weeks
Trial: 27081873
Drug: Low-Level Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Level Laser Therapy (LLLT) [λ=640 nm, SAEF=1.06 J/cm²]
Trial: 25623934
Drug: Morphine 1mg
RxNorm normalized name: MORPHINE 1MG/ML DEXTROSE 250ML
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine 1mg
Trial: 22935323
Drug: LAM-EC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM-EC group (received counseling for both LAM and EC with in-advance provision of one packet of EC pills)
Trial: 18172020
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to sustained-release bupropion (Level 2)
Trial: 18172020
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to sertraline (Level 2)
Trial: 18172020
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to extended-release venlafaxine (Level 2)
Trial: 18172020
Drug: Continue citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue citalopram and receive augmentation with sustained-release bupropion (Level 2)
Trial: 18172020
Drug: Continue citalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue citalopram and receive augmentation with buspirone (Level 2)
Trial: 14689413
Drug: Single-lumen tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-lumen tube with bronchial blocker
Trial: 10983674
Drug: High-dose GIK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose GIK therapy (insulin solution 225 IU, glucose, potassium, and mixed amino acids 11.4 g)
Trial: 10983674
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mixed amino acids 11.4 g)
Trial: 1543675
Drug: 0.1% gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% gentamicin sulphate cream
Trial: 4024909
Drug: TTS‐scopolamine (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TTS‐scopolamine (one patch)
Trial: 29808331
Drug: Topical chamomile
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical chamomile oleogel
Trial: 26848258
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day conivaptan
Trial: 26848258
Drug: 40 mg/day
RxNorm normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day conivaptan
Trial: 22788574
Drug: Moleca® shoes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moleca® shoes for six months for at least six hours daily
Trial: 17297176
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo cream)
Trial: 7526468
Drug: Vinorelbine (Navelbine)
RxNorm normalized name: vinorelbine Injection [Navelbine]
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (Navelbine) as a single agent
Trial: 7526468
Drug: Vinorelbine in
RxNorm normalized name: vinorelbine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine in combination with other agents (5-fluorouracil/leucovorin, mitomycin-C, ifosfamide, carboplatin, paclitaxel)
Trial: 29676193
Drug: Fidget spinners
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidget spinners (used by 48 children during the initial phase of treatment)
Trial: 29676193
Drug: Fidget spinners
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidget spinners (used by 48 children during both phases of treatment)
Trial: 28872486
Drug: Divalent iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalent iron (ferrous sulfate) 2 mg/kg/d for 5 months
Trial: 28872486
Drug: Trivalent iron
RxNorm normalized name: Iron trivalent, oral preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent iron (ferric polymaltose) 2 mg/kg/d for 5 months
Trial: 27271310
Drug: Midodrine (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midodrine (2.5-10 mg)
Trial: 27271310
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of midodrine and binder
Trial: 24638033
Drug: Reading in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading in color with specially prepared books pairing letters with colors; details on dosage and duration not specified.
Trial: 24638033
Drug: Reading experience
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading experience questionnaire administered post-intervention; details on dosage and duration not specified.
Trial: 20807303
Drug: Decaffeinated green
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated green tea (960 mL daily for 6 months)
Trial: 9726343
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/day)
Trial: 24034580
Drug: Buccal placement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal placement of 400-mcg misoprostol
Trial: 11387284
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of mifepristone administered on day LH + 2
Trial: 10402385
Drug: HCG administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG administered after endogenous LH surge (Group 2)
Trial: 10402385
Drug: HCG administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG administered before endogenous LH surge (Group 3)
Trial: 8607570
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 g of syrup)
Trial: 321508
Drug: Naftidrofuryl (Praxilene)
RxNorm normalized name: naftidrofuryl
DrugBank: Naftidrofuryl (DB13588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl (Praxilene) 300 mg daily for 90 days
Trial: 9272365
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccines (aP) from SmithKline Beecham (SB) or Chiron Biocine (CB)
Trial: 9272365
Drug: Whole-cell vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell vaccine (wP) from Connaught
Trial: 9272365
Drug: Diphtheria and
RxNorm normalized name: Diphtheria and tetanus vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphtheria and tetanus toxoids (DT) vaccine only
Trial: 9163637
Drug: roxithromycin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin (4 mg x kg(‐1) b.i.d.) for 12 weeks
Trial: 958757
Drug: Brief presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief presentation by a local pharmaceutical representative
Trial: 31328540
Drug: Stability and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stability and coordination exercises (20 min) as part of an 80 min cardiac rehabilitation programme, twice a week for 12 weeks
Trial: 23725523
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) with dietary supplementation of ascorbic acid (AA) (450 mg) for two weeks
Trial: 22050133
Drug: BCAA (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA (7 g)
Trial: 19931670
Drug: Prostacyclin (20,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostacyclin (20,000 ng/mL)
Trial: 16263778
Drug: Aggressive treatment/hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment/hospital setting (ATH)
Trial: 8422660
Drug: Albendazole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 7.5 mg/kg twice a day
Trial: 8422660
Drug: Albendazole 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 5.0 mg/kg three times a day
Trial: 3775071
Drug: 30 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 Gy in 10 daily fractions
Trial: 27676362
Drug: Promoting light-intensity
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promoting light-intensity activities of daily living (Control)
Trial: 22411639
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl (25 μg)
Trial: 17846853
Drug: Ertapenem 1
RxNorm normalized name: ertapenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem 1 g/day for 3 days
Trial: 17846853
Drug: Ertapenem 1
RxNorm normalized name: ertapenem 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem 1 g/day for >=5 days
Trial: 15943731
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose preoperative antibiotics (group A)
Trial: 15943731
Drug: Three-dose antibiotics
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose antibiotics (group B)
Trial: 15943731
Drug: 5-day perioperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day perioperative antibiotics (group C)
Trial: 12182212
Drug: Yohimbine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (8 mg orally twice a day)
Trial: 10485636
Drug: Zaleplon, 10
RxNorm normalized name: Zaleplon, 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon, 10 mg
Trial: 10485636
Drug: Zaleplon, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon, 20 mg
Trial: 10485636
Drug: Zaleplon, 5
RxNorm normalized name: Zaleplon, 5 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaleplon, 5 mg
Trial: 10485636
Drug: Zolpidem, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem, 10 mg
Trial: 8601845
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid infusion (1.3 g x kg‐1 x 24 h‐1)
Trial: 8601845
Drug: Trauma patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma patients (no amino acid infusion)
Trial: 1899682
Drug: Histamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine infusion starting at 0.2 microgram/kg/min, increased every 5 minutes by 0.1 to 0.2 microgram/kg/min until mean BP fell greater than 15 mm Hg or a dosage of 1.6 micrograms/kg/min was reached.
Trial: 30786186
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg daily for up to 180 days)
Trial: 30786186
Drug: Rivaroxaban (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban (10 mg daily during intervention period)
Trial: 20031857
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy plus percutaneous coronary intervention (PCI)
Trial: 15188337
Drug: Lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine (100 mg/day or less in case of renal insufficiency) and plasma exchanges (3/week for 3 weeks, 2/week for 2 weeks, then 1/week until seroconversion or clinical recovery) after short-term corticosteroids (oral prednisone 1 mg/kg/day for 1 week, then tapered and withdrawn within 1 week).
Trial: 9580391
Drug: Protocol 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 1: 200 ml 0.1N citric acid solution 10 min before 75 mg 13C-urea
Trial: 9580391
Drug: Protocol 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 2: 200 ml 0.1N citric acid solution simultaneously with 75 mg 13C-urea
Trial: 8061726
Drug: Ephedrine 20
RxNorm normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 20 mg plus caffeine 200 mg (EC)
Trial: 2498931
Drug: Lorazepam (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2.0 mg PO)
Trial: 2498931
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (0.3 mg, 1.0 mg, or 3.0 mg IV)
Trial: 4629075
Drug: Live adenovirus
RxNorm normalized name: Adenovirus type 7 vaccine live
DrugBank: Adenovirus type 7 vaccine live (DB14685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live adenovirus type 21 vaccine
Trial: 29876777
Drug: Probiotics (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (3.0 × 10^8 CFU/g Streptococcus thermophilus MG510 and 1.0 × 10^8 CFU/g Lactobacillus plantarum LRCC5193) daily for 4 weeks
Trial: 24646336
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin infusion discontinued at the onset of active labor (5cm cervical dilatation)
Trial: 24646336
Drug: Incremental oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incremental oxytocin infusion maintained until delivery
Trial: 24121096
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBT) plus drug withdrawal
Trial: 24121096
Drug: Placebo biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo biofeedback (PL) plus drug withdrawal
Trial: 24121096
Drug: Drug withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug withdrawal (MED) only
Trial: 15303313
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day plus medroxyprogesterone 2.5 mg/day (n = 6)
Trial: 15303313
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day (n = 9)
Trial: 9314976
Drug: Phase shift
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase shift contrast agent
Trial: 29230803
Drug: Insulin bolus
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin bolus
Trial: 28339831
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (FCM) targeting higher ferritin (400-600 µg/L)
Trial: 28339831
Drug: Intravenous ferric
RxNorm normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ferric carboxymaltose (FCM) targeting lower ferritin (100-200 µg/L)
Trial: 20332194
Drug: 48 h
RxNorm normalized name: DIAZOLIDINYL UREA 446 ug in 48 h / CLIOQUINOL 77 ug in 48 h / CHLORQUINALDOL 77 ug in 48 h / TIXOCORTOL PIVALATE 2 ug in 48 h / GOLD SODIUM THIOSULFATE 23 ug in 48 h / IMIDUREA 486 ug in 48 h / BUDESONIDE 0.8 ug in 48 h / HYDROCORTISONE BUTYRATE 16 ug in 48 h / 2-MERCAPTOBENZOTHIAZOLE 61 ug in 48 h / BACITRACIN 486 ug in 48 h / PARTHENOLIDE 2 ug in 48 h / DISPERSE BLUE 106 41 ug in 48 h / BRONOPOL 203 ug in 48 h CUTANEOUS PATCH [T.R.U.E. Test Panel 3.3]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 h prophylactic antibiotic therapy